150 related articles for article (PubMed ID: 27068265)
1. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.
Moya G; Dorado P; Ferreiro V; Naranjo MEG; Peñas-Lledó EM; LLerena A
Pharmacogenomics J; 2017 Jul; 17(4):378-381. PubMed ID: 27068265
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
3. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
6. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.
Naranjo ME; de Andrés F; Delgado A; Cobaleda J; Peñas-Lledó EM; LLerena A
Pharmacogenomics J; 2016 Oct; 16(5):485-90. PubMed ID: 27272044
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
8. Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay.
Bailliet G; Santos MR; Alfaro EL; Dipierri JE; Demarchi DA; Carnese FR; Bianchi NO
Mutat Res; 2007 Mar; 627(2):171-7. PubMed ID: 17194620
[TBL] [Abstract][Full Text] [Related]
9. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
10. Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.
Salyakina D; Roy S; Wang W; Oliva M; Akhouri R; Sotto I; Mulas N; Solano R; Fernández JR; Sanchez S; Shamshad U; Perlyn C; McCafferty-Fernandez J
Mol Genet Genomic Med; 2019 Sep; 7(9):e922. PubMed ID: 31389673
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.
Lazalde-Ramos BP; Martínez-Fierro Mde L; Galaviz-Hernández C; Garza-Veloz I; Naranjo ME; Sosa-Macías M; Llerena A
Pharmacogenomics; 2014 Feb; 15(3):339-48. PubMed ID: 24533713
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
13. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.
Isaza CA; Henao J; López AM; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):695-705. PubMed ID: 11294012
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of
P Sarmiento A; Dorado P; Borbón A; de Andrés F; LLerena A;
Pharmacogenomics; 2020 Nov; 21(17):1227-1236. PubMed ID: 33124522
[No Abstract] [Full Text] [Related]
16. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.
Niewinski P; Orzechowska-Juzwenko K; Hurkacz M; Rzemislawska Z; Jaźwinska-Tarnawska E; Milejski P; Forkasiewicz Z
Eur J Clin Pharmacol; 2002 Nov; 58(8):533-5. PubMed ID: 12536989
[TBL] [Abstract][Full Text] [Related]
18. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.
McLellan RA; Oscarson M; Seidegård J; Evans DA; Ingelman-Sundberg M
Pharmacogenetics; 1997 Jun; 7(3):187-91. PubMed ID: 9241658
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism in a Mexican American population.
Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
